Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OPN-305
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 09, 2017
Lead Product(s) : OPN-305
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OPN-305
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 16, 2015
Lead Product(s) : OPN-305
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : MD Anderson Cancer Center | Montefiore Medical Center | Moffitt Cancer Center | New York Presbyterian Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OPN-305
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 20, 2013
Lead Product(s) : OPN-305
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
